Barinthus Biotherapeutics
BRNS
11 hedge funds and large institutions have $15.7M invested in Barinthus Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
10.2% more ownership
Funds ownership: 16.93% → 27.13% (+10%)
15% less funds holding
Funds holding: 13 → 11 (-2)
32% less capital invested
Capital invested by funds: $23.2M → $15.7M (-$7.51M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MGIM
M&G Investment Management
London,
United Kingdom
|
+$17.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.19M |
| 2 |
Millennium Management
New York
|
-$132K |
| 3 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$70.1K |
| 4 |
Morgan Stanley
New York
|
-$5.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
Alphabet Inc
Mountain View,
California
| $4.84M | – | – | – |
|
|
HH
2
HSG Holding
Na,
Hong Kong
| $4.55M | – | – | – |
|
|
DF
3
DC Funds
Mclean,
Virginia
| $2.06M | – | – | – |
|
|
LIP
4
Liontrust Investment Partners
London,
United Kingdom
| $1.9M | – | – | – |
|
|
BCM
5
BlueCrest Capital Management
St Helier,
Jersey
| $1.74M | – | – | – |
|
|
JHU
6
Johns Hopkins University
Baltimore,
Maryland
| $345K | – | – | – |
|
|
7
Millennium Management
New York
| $96K | -$132K | -30,974 | -50% |
|
|
IIM
8
Ipswich Investment Management
Beverly,
Massachusetts
| $75K | -$70.1K | -16,500 | -41% |
|
|
9
Morgan Stanley
New York
| $40K | -$5.27K | -1,241 | -9% |
|
|
10
UBS Group
Zurich,
Switzerland
| $17K | +$20.1K | +4,726 | +1,023% |
|
|
MGIM
11
M&G Investment Management
London,
United Kingdom
| $15.6K | +$17.4M | +4,108,752 | +377% |
|
|
12
Tudor Investment Corp
Stamford,
Connecticut
| – | -$1.19M | -266,927 | Closed |
|
BRNS Hedge Fund Activity: Q3 2022 in Review
11 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q3 2022, worth a combined $15.7M — down 32% from $23.2M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BRNS and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was M&G Investment Management, adding an estimated $17.4M. The largest seller was Tudor Investment Corp, exiting entirely with an estimated $1.19M sold.
- 11 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q3 2022, down from 13 in Q2 2022.
- Funds reported $15.7M of Barinthus Biotherapeutics stock for Q3 2022, down 32% quarter-over-quarter.
- 0 funds opened new Barinthus Biotherapeutics positions in Q3 2022 and 2 closed out, a net change of -2 holders.
- The largest Barinthus Biotherapeutics buyer in Q3 2022 was M&G Investment Management, an estimated $17.4M added.
- The largest Barinthus Biotherapeutics seller in Q3 2022 was Tudor Investment Corp, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2022.